A randomized, placebo-controlled trial investigating the acute and chronic benefits of American Ginseng (Cereboost®) on mood and cognition in healthy young adults, including in vitro investigation of gut microbiota changes as a possible mechanism of action

• Published in: European journal of nutrition 2022-02, Vol.61 (1), p.413-428
• Main Authors: Bell, Lynne, Whyte, Adrian, Duysburgh, Cindy, Marzorati, Massimo, Van den Abbeele, Pieter, Le Cozannet, Romain, Fança-Berthon, Pascale, Fromentin, Emilie, Williams, Claire
• Format: Article
• Language: English
• Subjects: Acetic acid; Acetylcholine; Attention task; Chemistry; Chemistry and Materials Science; Clinical trials; Cognition; Cognition & reasoning; Cognitive ability; Digestive system; Double-Blind Method; Ecosystem; Gastrointestinal Microbiome; Ginseng; Humans; Intestinal microflora; Memory; Microbiomes; Microbiota; Middle Aged; Mood; Neurotransmitters; Nutrition; Original Contribution; Panax; Placebos; Plant Extracts - pharmacology; Propionic acid; Short term memory; Supplements; Young Adult; Young adults
• ISSN: 1436-6207; 1436-6215
• DOI: 10.1007/s00394-021-02654-5

Purpose Cereboost®, an American ginseng extract, has shown improved short-term memory and attention/alertness in healthy young and middle-aged individuals, potentially via modulation of the gut microbiome and upregulation of neurotransmitters such as acetylcholine. Here, we explored the effects of Cereboost® on cognition and mood in the first 6 h post intervention (acute), after 2 weeks daily supplementation (chronic), and whether 2 weeks daily supplementation altered the response to a single acute dose (acute-on-chronic). A concurrent in vitro study evaluated effects of repeated Cereboost® administration on human gut microbiota. Methods Cognitive effects of Cereboost® were assessed using a double-blind, randomized, placebo-controlled clinical trial, with 61 healthy young adults. Modulation of the gut microbiome was concurrently modelled using the Simulator of the Human Microbial Ecosystem (SHIME®), using a young adult donor. Results Consistent with previous findings, Cereboost® improved working memory and attention during the immediate postprandial period; effects that were amplified following two weeks’ treatment (acute-on-chronic) compared to acute testing alone. Chronic supplementation improved cognition on an acetylcholine-sensitive attention task and improved mental fatigue and self-assurance aspects of mood. The parallel in vitro study revealed significantly increased acetate, propionate, and butyrate levels in simulated proximal and distal colon regions, linked with observed increases in Akkermansia muciniphila and Lactobacillus . Conclusion This study confirmed the promising effects of Cereboost® on cognitive function and mood, while suggesting a possible link to alterations of the gut microbiome and modulation of acetylcholine. Further studies will be required to unravel the underlying mechanisms that are involved. Registration The study was pre-registered at ClinicalTrials.gov on 6th July 2018 (Identifier: NCT03579095).